Cyclophilins are a family of peptidyl-prolyl cis-trans isomerases whose enzymatic activity can be inhibited by cyclosporin A. Sixteen cyclophilins have been identified in humans, and cyclophilin D is a unique isoform that is imported into the mitochondrial matrix. Here we shall (i) review the best characterized functions of cyclophilin D in mitochondria, i.e. regulation of the permeability transition pore, an inner membrane channel that plays an important role in the execution of cell death; (ii) highlight new regulatory interactions that are emerging in the literature, including the modulation of the mitochondrial F1FO ATP synthase through an interaction with the lateral stalk of the enzyme complex; and (iii) discuss diseases where cyclophilin D plays a pathogenetic role that makes it a suitable target for pharmacologic intervention.
Introduction
Cyclophilins (CyPs) are ubiquitous proteins endowed with peptidyl-prolyl cis-trans isomerase (PPIase) activity [1, 2] that have been highly conserved during evolution. CyPs can be identified in the genomes of mammals, plants, insects, fungi and bacteria; they all share a common domain of approximately 109 amino acids, the CyPlike domain [3] . In humans 16 unique CyPs have been found [3] , with CyPA representing the prototype of the family [1, 2] . After binding to the CyP ligand cyclosporin (Cs) A, the PPIase activity is inhibited [4] , and the CsA/CyPA complex binds to and inhibits the cytosolic phosphatase calcineurin [5] resulting in immunosuppression [6, 7] . Together with the FK506-binding proteins (FKBP, structurally unrelated PPIases that share with CyPs the ability to inhibit calcineurin after binding their cognate inhibitory ligand FK506), they constitute the family of immunophilins [8] . Work with mutants of human CyPA has clearly separated the PPIase activity of the protein from CsA binding and calcineurin inhibition [9] , suggesting that CyPs have specific cellular functions that may be of importance for a variety of processes relevant to human disease [3] .
The evolutionary conservation of the PPIase activity among species suggests that this can be an important function of the CyPs and FKBPs [10] , as shown by the Drosophila NinaA PPIase, which serves as a chaperone for specific rhodopsin isoforms [11] . Yet, and somewhat surprisingly, Saccharomyces cerevisiae mutants lacking all 12 yeast immunophilins were viable, and the phenotype of the dodecuplet mutant resulted from simple addition of the subtle phenotypes of each individual mutation [12] . This striking finding led these authors to conclude that CyPs and FKBPs do not play an essential general role in protein folding, and to propose that each CyP and FKBP instead may regulate a restricted number of unique partner proteins [12] . In keeping with this prediction, CyPs have been shown in recent years to be involved in a variety of pathophysiological processes including inflammation and vascular dysfunction [13] [14] [15] [16] [17] , wound healing [18] , innate immunity to HIV [19] , hepatitis C infection [20] , host-parasite interactions [21] , tumor biology [22] and regulation of the mitochondrial permeability transition pore (PTP) which is mediated by the mitochondrial isoform of the enzyme, CyPD [23] [24] [25] [26] . The existence of specific functions is also suggested by the presence of tissue-and organelle-specific isoforms characterized by the combination of the signature CyP domain with the proper targeting and/or retention sequence(s) [3] .
Cyclosporin A, cyclophilins and calcineurin
Cs are cyclic undecapeptides produced by several fungal taxa including the common strain Tolypocladium inflatum. CsA is the most studied [27] ; its ability to prevent the immune response has revolutionized medicine, allowing organ transplantion to become a standard therapeutic practice. Interaction of CsA with cytosolic CyPA generates a complex that acquires the ability to bind to, and inhibit, the cytosolic, Ca 2+ -activated phosphatase calcineurin [5] ; as a consequence of calcineurin inhibition, its substrate phospho-NFAT is no longer dephosphorylated and therefore unable to translocate to the nucleus and trigger the IL-2-dependent activation of the immune response against the transplant [6, 7] . Recently, an important discovery has been made showing that translocation of the cytosolic pro-fission protein Drp1 to mitochondria requires its calcineurindependent dephosphorylation at Ser637 that is inhibited by CsA [28] . Thus, CsA also affects mitochondrial shape and function via calcineurin inhibition independent of its interactions with matrix CyPD (see below), a concept that should be taken into account when interpreting the complex effects of CsA on mitochondrial function and cell survival [29] . Separation of the calcineurin-dependent and -independent effects of Cs has been greatly helped by nonimmunosuppressive analogs of CsA (such as MeVal-4-Cs, NIM811 and Debio 025) that maintain the ability to bind to, and inhibit CyPs but not calcineurin [24, [30] [31] [32] . Like Cs these drugs likely inhibit all CyPs to varying degrees [3, 26] , a point that should be kept in mind when the mitochondrial effects of these molecules are evaluated. A recent study has identified a small-molecule inhibitor based on aryl 1indanylketones that discriminates between CyPA and CyPB in vitro, a proof of principle that holds great promise for the development of isoform-specific CyP inhibitors [33] . The rapidly growing field of CyP biochemistry, pharmacology and pathophysiology is beyond the scope of this article, but the interested reader can find further information in recent reviews [3, 34, 35] .
Cyclophilin D and the permeability transition
CyPD is the unique mitochondrial isoform of CyP in mammals [23] [24] [25] . Its identification was prompted by the demonstration that CsA affects mitochondrial Ca 2+ fluxes [36] through an effect that could be traced to desensitization of the PTP [37] [38] [39] [40] , an inner membrane highconductance channel whose molecular composition remains an unanswered question [41] [42] [43] [44] [45] . The PTP plays a key role in cell death and has proved to be a viable target for therapeutic intervention in a variety of diseases, most notably ischemia-reperfusion injury of the heart and brain, muscular dystrophies, neurodegeneration and cancer [41] [42] [43] [44] [45] . Genetic ablation of the Ppif gene (which encodes for CyPD) in the mouse has demonstrated that CyPD is the mitochondrial receptor for CsA, and that it is responsible for modulation of the PTP but not a structural pore component [46] [47] [48] [49] . As discussed more in detail elsewhere [42] , the effect of CsA on the PTP is best described as "desensitization" in the sense that the PTP becomes more resistant to opening after the uptake of Ca 2+ and Pi in standard in vitro assays in isolated mitochondria; yet pore opening readily takes place for Ca 2+ -Pi loads that are about twice those required in wild-type mitochondria. A major step forward in our mechanistic understanding of the role of CyPD in PTP modulation has been the discovery that CyPD ablation (or treatment with CsA) unmasks an inhibitory site for Pi, which is the actual PTP desensitizing agent [50] . Unless Pi is present, the sensitivity of the PTP to Ca 2+ and to other agents of pathophysiological relevance is identical in naïve and CsA-treated wild type mitochondria, as well as in CyPD-null mitochondria. This finding has important implications for our understanding of PTP regulation. Indeed, as also noted elsewhere [50] (i) it is fortunate that Pi was included in mitochondrial swelling assays of PTP in vitro, so that the desensitizing effect of CsA was not missed; and (ii) the Pi-dependence of PTP inhibition by CsA and CyPD ablation may be just one example of the factors that control the PTP sensitivity to inhibitors in situ. Thus, extreme caution should be exerted when results from in vitro studies are extrapolated to the status of the PTP in vivo. Fig. 1 Indeed, the existence of additional effector sites on the PTP is strongly suggested by the large variety of PTP inducers and inhibitors [51] .
Cyclophilin D interactions with other proteins
An interaction of CyPD with the adenine nucleotide translocator (ANT) has been described both in detergent extracts of mitochondria and after purification of the ANT [52] . These results have been interpreted within the framework of the PTP being formed by the ANT and regulated by CyPD binding [53] , possibly with the contribution of VDAC as well [54] . As we have noted previously [55] , in these protocols several proteins other than the ANT bound to CyPD in a CsAinhibitable manner [52] . Notably, CyPD bound equally well to ANT purified from rat liver and yeast, yet the permeability transition is not inhibited by CsA in yeast mitochondria [56] . Our concerns about the significance of the CyPD-ANT(-VDAC) interactions in PTP regulation are reinforced by the demonstration that ANT-null mitochondria still display a CsA-sensitive permeability transition, although this requires higher loads of Ca 2+ and Pi [57] , and that VDACs are dispensable for PTP opening [58, 59] . It should be noted that the identification of the ANT as a CyPD-binding protein was obtained by immunological methods rather than by direct protein determination by sequencing or mass spectroscopy [52] . Recent work has shown that the polyclonal antibody used in these studies is not detecting ANT1 but rather the Pi carrier [60] , which has now been incorporated in the model of the PTP proposed by the Halestrap laboratory [61] , a working hypothesis that in our opinion needs to be validated by more stringent tests.
Further regulatory interactions of CyPD are emerging in the literature. A recent study has demonstrated the existence of a complex mitochondrial chaperone network that involves Hsp90, its related molecule TRAP-1, and CyPD [62] . CyPD bound to the complex would no longer be available for PTP opening. CyPD displacement from this complex by selective Hsp90 antagonists like Shepherdin could disable this protective network and reactivate the PTP with the onset of mitochondrial depolarization, release of cytochrome c, and massive cell death. Since the Hsp90-TRAP-1-CyPD interactions are particularly prominent in tumor cells, this strategy has been successfully used for their selective killing [62] .
In keeping with previous results on the role of GSK-3 in PTP regulation [63] , we have recently found that a small fraction of ERK associates to mitochondria, where it can be activated to phosphorylate (hence inactivate) GSK-3 resulting in PTP desensitization. Of note, CyPD could be co-immunoprecipitated with ERK2 and GSK-3, and it was Ser/Thr phosphorylated. Phosphorylation correlated with CyPD binding to GSK-3 and with PTP opening; and both events were inhibited by the selective GSK-3 inhibitor indirubin-3′-oxime [64] .
A recent study has demonstrated an interaction of CyPD with Bcl2 that could be displaced by CsA. In these protocols, addition of CsA increased tBid-dependent release of cytochrome c from mitochondria under conditions that did not cause the opening of the PTP, suggesting a PTP-independent effect of CyPD (and CsA) that is relevant to mitochondrial triggering of apoptosis [65] . Consistent with previous results [66] , CyPD overexpression made cells more resistant to apoptotic stimuli, a finding that is difficult to reconcile with a predominant effect of overexpression on the PTP [65, 66] .
Cyclophilin D interactions with the F1FO ATP synthase
The F1FO ATP synthase is a 600 kDa multisubunit complex located in the inner mitochondrial membrane whose catalytic part (F1) and lateral stalk protrude into the matrix compartment where CyPD is located, while the FO moiety and the remaining portion of the lateral stalk are embedded into the inner membrane [67, 68] . We recently documented that CyPD interacts with the ATP synthase of bovine heart mitochondria in protocols based on both blue native electrophoresis and immunoprecipitation of complex V after mild detergent extraction [69] . Cross-linking with the cleavable bifunctional reagent dimethyl 3,3-dithiobis-propionimidate, which reacts with the primary amines of two interacting proteins at an average distance of about 8 Å [70] , demonstrated that CyPD forms a cross-linked complex with OSCP, b, and d subunits in an apparent ratio of 1:1:1:1 [69] , supporting the interaction of CyPD with the extrinsic part of the lateral stalk. The cross-linker also forms smaller complexes (such as b-d and b-OSCP) [71] , and so far we have been unable to resolve the CyPD direct interactor(s) on the ATP synthase. Since only subunit b was detected amongst CyPD-binding proteins in affinity purification-based protocols (C. Baines, personal communication), we suspect that the direct interaction of CyPD may occur with the surface area of subunit b exposed to the mitochondrial matrix [67] . It is important to stress that interaction of CyPD with the enzyme complex is favored by Pi and competed by CsA. Importantly, CyPD binding has major functional consequences, with a decrease of specific activity that can be reversed by CsA-dependent CyPD displacement [69] . Whether this striking analogy with Pi-dependent PTP regulation by CyPD [50] indicates a link between the two processes remains a matter for future studies. Fig. 2 illustrates the putative site(s) of interaction of CyPD with the lateral stalk of the F1FO ATP synthase, depicted here in the dimeric form, which is considered the "building block" of higher order, oligomeric forms of the enzyme that optimize its catalytic performance; oligomeric forms are considered to represent the physiological state of F1FO ATP synthase in the inner membrane [72, 73] . There is a wide variability in the angle formed by the monomers when they associate into dimers [74] , and it is tempting to speculate that CyPD displacement by CsA may activate the enzyme by favoring the formation of oligomers characterized by a higher activity. Conversely, CyPD binding could switch the enzyme to a different oligomeric form (i.e. a state with a different angle between monomers), with lower catalytic activity [69] . Finally, it should be mentioned that the stimulatory effect of CsA is lost in Ppif −/− mitochondria, indicating that it is mediated by CyPD, while assembly of the ATP synthase is unaffected by CyPD ablation [69] .
Cyclophilin D in disease
Ppif −/− mice do not display an overt disease phenotype [46] [47] [48] [49] . In a number of independent laboratories, CyPD-null mice were born at the expected Mendelian ratios [46] [47] [48] [49] and were apparently identical to wild-type, Ppif +/+ C57BL/6 animals, findings that indicate that CyPD is dispensable for embryonic development and viability [47] . It is possible that lack of a phenotype at birth may be due to adaptive responses whereby the decreased sensitivity of the PTP to Ca 2+ is bypassed by compensatory mechanisms that are not detectable in isolated mitochondria. It should also be noted that the physiological role of CyPD may change during development, as neonatal Ppif −/− mice are more sensitive to ischemia-reperfusion injury of the brain [75] rather than more resistant as are adult mice [49, 75] . However, Ppif −/− mice display increased anxiety, facilitation of avoidance behavior, and they develop adult-onset obesity independent of food and water intake [76] suggesting that they may develop specific phenotypes with aging. It should also be recalled that CyPD overexpression desensitized cells from apoptotic stimuli, indicating that CyPD may also play a role as a cell survival-signaling molecule acting on targets other than the PTP [65, 66] .
CsA and its non-immunosuppressive analogs MeVal-4-CsA, NIM811 and Debio 025 have been used in disease paradigms where the PTP has been causally implied such as ischemia-reperfusion injury of the heart and brain, TNF-α-dependent fulminant hepatitis, and collagen VI myopathies (reviewed in [42, 77] ). As should be apparent from the preceding paragraphs, the interpretation of these results is not straightforward because (i) all CyPs, not only CyPD, are likely inhibited to varying degrees by these drugs; (ii) the recent finding that Drp1 dephosphorylation depends on calcineurin [28] demands a reinterpretation of the protective effects of CsA in many animal models of human disease since CsA's mitochondrial effects may in part depend on inhibition of Drp1-mediated fission; and (iii) the PTP is not directly affected by CsA but rather desensitized through the inhibitory effects of Pi, and the PTP is insensitive to CsA if the Pi concentration is not high enough [50] . The only models that allow conclusions to be made on the role of CyPD in disease are those based on the genetic ablation of CyPD (Ppif −/− mice), with the clear understanding that this animal model explores the role of CyPD, not of the PTP, in the considered disease paradigm.
Convincing evidence obtained in adult Ppif −/− mice causally links CyPD to ischemia-reperfusion injury of the heart [46, 48] and brain [49, 75] , as infarct size was reduced in CyPD-null adults compared to wild-type or littermate controls. These studies corroborate the conclusions of previous studies based on the use of CsA in ischemic isolated hearts [78] and in infarcted patients [79] , in brain damage by hypoglycemia [80] , hyperglycemia [81] , middle cerebral artery occlusion [82, 83] , and traumatic injury [84, 85] . Ppif −/− mice displayed a striking resistance to development of axonopathy in a model of autoimmune encephalomyelitis [86] , and to disease progression after crossing with superoxide dismutase 1 mutant mice [87] , suggesting that CyPD-dependent mechanisms may be critical in the neurodegenerative aspects of demyelinating and motor neuron diseases. Ablation of CyPD has also been shown to substantially improve learning, memory and synaptic function in a mouse model of Alzheimer's disease, where it also alleviated reduction of long-term potentiation mediated by the amyloid β peptide [88] .
The best characterized case involving CyPD in pathology in vivo is represented by collagen VI diseases [89] , a set of genetically heterogenous conditions that cause Bethlem myopathy [90] , Ullrich congenital muscular dystrophy [91, 92] and myosclerosis [93] in humans. Following the discovery that the mouse model of the disease (Col6a1 −/− lacking collagen VI [94] ) has a striking mitochondrial involvement in affected muscles that could be cured with CsA [95] and Debio 025 [32] , we have recently shown that Ppif −/− Col6a1 −/− mice lacking both CyPD and collagen VI are indistinguishable from syngenic wild type mice [96] , providing a clear proof of principle for the causal involvement of CyPD in the development of the disease that matches the promising results obtained with CsA in patient cultures [97] and in a pilot trial [98] , and with the non-immunosuppressive CyP inhibitor Debio 025 in the collagen VI myopathic mouse [32] . Although the therapeutic outcome was less dramatic, these results are matched by those obtained in Ppif −/− Scgd −/− mice, which showed markedly less dystrophic disease in both skeletal muscle and heart than Scgd −/− mice lacking δ-sarcoglycan [99] . In addition, Ppif −/− Lama2 −/− mice exhibited a significantly extended survival compared to Lama2 −/− mice and treatment of the mdx mouse model of Duchenne muscular dystrophy with Debio 025 resulted in markedly less dystrophic disease [99] . The mouse disease models in which the effects of CyPD ablation have been investigated are summarized in Table 1 .
Conclusions
We think that understanding the pathophysiology of CyPD will provide novel perspectives to the development and use of CyP inhibitors of increasing specificity in CyPD-dependent diseases. In addition, the emerging complexity of the mitochondrial effects of CyPD (hence of CsA) should induce some caution in interpreting the results obtained with CyP inhibitors and CyPD ablation as solely resulting from modulation of the PTP. Scgd −/− (muscular dystrophy linked to sarcoglycan deficiency) Protection [99] Lama2 −/− (muscular dystrophy linked to laminin deficiency) Protection [99] Col6a1 −/− (muscular dystrophy linked to collagen VI deficiency Protection [96] 
